Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Raltegravir (Isentress®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in treatment-experienced adults in accordance with British HIV Association (BHIVA) guidance. Raltegravir (Isentress®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | raltegravir (Isentress®) | |
| Formulation | 400 mg film-coated tablet | |
| Reference number | 254 | |
| Indication | In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Submission type | Full | |
| Status | Recommended | |
| Advice number | 1808 | |
| NMG meeting date | 17/09/2008 | |
| AWMSG meeting date | 15/10/2008 | |
| Ratification by Welsh Government | 18/11/2008 | |
| Date of issue | 25/11/2008 | |